The targeted therapies erlotinib and cetuximab, in combination with standard chemotherapy regimens, are well tolerated and have very encouraging activity in recurrent/metastatic head and neck squamous cell carcinoma, according to two presentations at the American Society of Clinical Oncology (ASCO) 2007 Annual Meeting in Chicago.
Stereotactic radiotherapy is increasingly gaining favor as an attractive alternative to conventional surgery of the skull base and head and neck.
Part 2 of this article will discuss treatment options for skull base tumors.
Otolaryngologist Martin L. Hopp, MD, PhD, of Cedars-Sinai Hospital in Los Angeles, believes that in-office computed tomography (CT) scanning is the trifecta of care for otolaryngologists and their patients.
Contrary to popular belief, CMS is in the business of paying for quality care, not just the volume of care provided.
For years, radical surgery was the only treatment for head and neck cancer (HNSCC).
